Charlie. Thank you,
for excellent team foundation, interest receive patients an it. considerably Cushing's that than Quorum patients a assumed. business endocrinologists there Our built of eligible syndrome first. increasingly to Cushing's with once a is believe patients was a solid syndrome more there commercial syndrome puts with that is medication who are the yet many by on and patients Cushing's treatment life-saving have Meeting promoted are
are to of and CATALYST our growth our syndrome substantial notably improve optimistic and recently patients, these We most making screening potential initiated of investments Cushing's the extremely the study are treatment business. about
and quarter, increase first an patients a Korlym prescribing we of the saw receiving of in the in medication. number the physicians number In
revenue XXXX $XXX to our raising million are $XXX million. to guidance We range
the efforts are progress therapeutic many also clinical be that the development Since disorders. research built powerful serious cortisol very on hypothesis modulation of our can in We have development encouraged programs. a our and by inception, mechanism
our Our cortisol's the modulating progesterone progesterones glucocorticoid activity Korlym's compounds receptor, modulate cortisol which not are GR. receptor receptor of so identical. bind not proprietary the -- to our high. approved when activated without the They or cortisol activity, Interestingly, they effects don't to effects. is while do compounds cause serious are on modulate levels of off-target binding the some and products
Some cross not. others barrier, the blood-brain do
best Some disease. more are perform in others of tumors, cometabolic solid models
be to variety have disorders. of global a qualities effects. study tissue more diverse specific, wide Some appear to These others allow us
and are programs cortisol and, of Syndrome. and prostate Cushing's cancer, in miricorilant. conducting proprietary of -- we relacorilant, ovarian, with Currently, selective X course, ALS, modulators, our dazecorilant adrenal NASH
NASH the expect preclinical months, data enrollment Corcept. trial and of IIb we have completion compounds gradient initiation our very and time a patients development. in Rosella studies, clinical for This Ib the of NDA Catalyst of additional and with DASL Phase In our a miricorilant studies Grace, in and NASH. relacorilant is of submission for syndrome, Cushing's next exciting Phase We XX from in of
nGredient. of Phase a in We Relacorilant is modulator. evaluating cortisol hypercortisolism X treatment selective III the in trials: relacorilant are Grace
and in experienced by Korlym and progesterone hypokalemia, efficacy Phase a safety control achieves not receptor, compelling. in serious potassium, PR-related of Korlym's vaginal not well thickening it II of does effect thickening induced effects, Unlike effect mechanism, Frontiers side and receptor. in endocrinology termination its of the the experienced including a of does discontinuation. of glucocorticoid XXXX. as cause as glucose for a were or vaginal syndrome. relacorilant-induced patients variety it Like improvements for pregnancy, cause in with trial. There The and symptoms does and hypokalemia low signs in cortisol endometrial Korlym, other is in competing were bind and drug-induced not side short, endometrial results bleeding so hypertension no PR different By published to instances pivotal hypokalemia. no meaningful of at XX% a also bleeding. leading relacorilant data Relacorilant's Cushing's by Korlym, cause Patients trial were July
submission complete all Cushing's to plan necessary the for serve that trial. to Grace we enrollment We in syndrome, the in will patients first as our identified to we GRACE plan We are pleased our share half the XXXX. to complete in which basis submit weeks. have of the NDA coming
hypercortisolism, effects of syndrome Phase in Cushing's but patients gradient health an III caused in rapid less Cushing's their hyperplasia. experience including is whose second a syndrome poor, adrenal outcomes trial studying adrenal by this risk of is higher death. or with often etiology decline, adenoma relacorilant Our Patients a are
of that from to NDA in will not Gradient, the these While care findings patients. do depend data on syndrome its our expect we we improve expect Cushing's do
in patients. a us the is is We in higher prevalence diabetes. with now type will in X studies the these double-blind, physicians are patients will enter than X,XXX-patient Korlym. examining hypercortisolism difficult to the general Patients our have may CATALYST and and XX identify of substantially design enrolling in diabetes diagnosed is placebo-controlled be type Phase in that X a control initiated conducted study States from participating enable of also with CATALYST better that excited most of its Data hypercortisolism study Many with helped prominent trial catalysts, largest the care diabetologists over United IV recently for independent patients. study are years to randomized, patients of kind. population. hypercortisolism The the last prevalence found which Catalyst the
expect complete by this We end enrollment the to of year.
program investor is oncology and cell first controlled by of beneficial X the to relacorilant, many by the the trial likely University our Chicago is mechanisms, our prominent increasing at apoptosis, solid to selective that of modulator, death induce enhance by mechanism addition Our researchers. the tumors. meaningful II women our the confirmed against of chemotherapy One works later cortisol successful testing ovarian effect blunting other meant in benefit platinum-resistant of gates women Cortisol is chemotherapy, with chemotherapy program of by suppressing in provided cancer, effect apoptosis. postulated Phase in Relacorilant cortisol's And the effect. anti-apoptotic anticancer study.
or disease women's resensitize to on previous some women. have of in including effects chemotherapy's the treatment, these disease X more previous to beneficial taxanes, progressed appear relaturn While lines
and a survival net than nappaclitaxel they to group nappaclitaxel the took burden relacorilant women statistical who longer relacorilant in additional those received the a with X duration received took paclitaxel who to Perhaps the -- were before compared intermittent p-value and who statistically were plus significant study who response received group who after We experienced intermittently relacorilant nab-paclitaxel patients that live the after of arm, alone. who the of in effect more intermittent XX% years exhibited live approached progression-free relacorilant comparator alone. also improvement Those versus day day the of even received the those monotherapy. start important, in the side compared only significance. no Nappacclitaxel, their day received
XXXX Rosella's Planned featured Meeting. either overall women submitted publication ASCO presentations nab-paclitaxel been in have XXX endpoint Rozella, a nab-paclitaxel meetings is were endpoint. the is design study. review in platinum-resistant at Annual Phase Oncology, or and trial enrollment pivotal alone. Phase Medical tracks Clinical the to secondary progression-free patients. study recurrent this III European with of key cancer primary Society from American is survival Society for results XXXX randomized our enrolling The for relacorilant II ESMO Oncology, peer plus our X:X survival, and XXXX ovarian closely podium The and receive
Trials in clinicians study with in leading this the and European Group collaboration conducting States the are of Network the Oncology Group Europe. We Oncology United Gynecological Gynecological in from
We complete year. end to in are on this the by Rosella enrollment of track
cortisol prescribed us to blocking patients modulation II mechanism which is prostate antagonist a view, has prove the and II nab-paclitaxel ovarian benefit we relacorilant deck potential new widely with improved standard resurgent have relacorils Our our to with major burden, replicate treated important may an progression-free is useful goal plus Leading why A potential in enzalutamide, in of Cortisol positive pathway. experience the Phase with sight survival and by stimulation a in their an disease. receptor tumor the reason is second of results. cancer oncologists without care overall androgen gynecological growth medical Phase simply increased advance platinum-resistant women told important by become that, cancer. eventually constitute
cortisol tumor to androgen stimulation, activity their stimulate switch of growth. to Deprived
By route. is had seeks our cancer hypothesis midyear, therapies to to cancer initial the Our Cortisol escape blunt system. that plan cortisol will randomized before relacorilant third plus androgen to an II deprivation A of this suppresses modulator close the tumors the a treat a prostate which response. patients Chicago to by with enzalutamide of body's of prostatectomy. begin placebo-controlled adding collaborators therapy Phase at trial therapeutic tumor in system, patients effectiveness immune mechanism enhancing have immune immune the made the intended stimulate University these
a modulator adding enhance as that effectiveness checkpoint immunotherapies is cortisol the hypothesis inhibitors, therapies. may of such to those Our
has an Garik's excess in We our randomized form in known illness selective muscular enrolling treating Azencorilant is and XXX-patient a tumors briskly as Tazecorilant cancer. plus treatment. promise relacorilant checkpoint in trial effective in is double-blind improving cortisol with reducing great this rarely Lou advanced produce trial -- is and whose placebo-controlled neuroinflammation motor Phase of commonly animal Pembrolizumab atrophy. Phase need adrenal patients. of ALS, shown for of a with II inhibitor is cancer models with that ALS, as of adrenal conducting a ALS urgent patients the devastating dazzles, are modulator better Ib patients monotherapy performance PD-X disease pembrolizumab, cortisol.
academic We are leading conducting Trical, consortium this Europe. with collaboration important in in the study ALS
next We are on track year. by early dazzles enrollment in to complete
oral of and demonstrate receive our liver In disorder to patients program for a NASH millions continues NASH. turn in great patients serious afflicts United of occurred a greater States. the -- I'll patients elevations in exhibited medication had rarely more improvement rapid ALT that expected reductions seen treatment miricorilant miricorilant large albeit AST. and in and and period we liver liver fat of The in fat, liver these enzymes, over transient but also rapidly much any was substantial than has in to study, to promises NASH, prior Finally, who treatment. the
without cause range appear Our liver which causing to Phase our completed dose-finding excessive enrollment, large Ib substantially identified that doses all lower study, has originally liver has tested of in a fat reductions than doses, herritation.
extremely study to quarter programs to to of trial share the the a development this we results our even are in midyear continues our II In profits business, about substantial plan Phase expect by conclusion, from year. syndrome Cushing's of fourth We which the potential advance. and start as growth optimistic generate
We come. this years revenue expectations year for have and raised to for our growth expect
Catalyst, screening the goes study, population whose is represents newest and a frequently undiagnosed. Our investment treatment hypercortisolism, difficult to diabetes a syndrome to patients by Cushing's caused improve of significant to control who's
activity development generating diseases. Our validates our -- has cortisol current to and offer can way examples, serious treat Cushing's to programs patients and there be other wide straightforward a and cancer, NASH a substantial -- range but that are will is evidence effective to with others. the are disorders. syndrome benefits ovarian ALS that long-held reducing increasing potential of cortisol belief modulation treat
development caused and proprietary by studies and will relacorilant's hypercortisolism. potentially disease and data platinum-resistant clinical cancer, from of portfolio programs next will XX cortisol different in attributes. the addition to recurrent dazecorilant submit diabetes In large relacorilant many ALS ovarian in we in in modulators we months, and Cushing's complete have very Cushing's our our NDA In controlled other enrollment liver will syndrome selective syndrome miricorilant, with see
trial will We Phase in with also IIb a NASH. begin patients
As is possible. loyal employees investors creative I for exciting Corcel. dedicated I an that thank said, making and for time our it
I'll for stop here questions.
